

Claims

1 A process for producing antibodies to
cholesteryl ester transfer protein (CETP) in a mammal
5 that comprises the steps of:

(a) immunizing said mammal with an
inoculum containing a vehicle in which is dissolved or
dispersed a recombinant DNA molecule comprising a DNA
sequence that contains (i) a sequence encoding a CETP
immunogen linked to (ii) a promoter sequence that
controls the expression of said-CETP immunogen DNA
sequence in said mammal, said CETP immunogen being an
immunogenic polypeptide having a CETP amino acid residue
sequence, said immunization providing an amount of said
15 recombinant DNA molecule sufficient to induce antibodies
to CETP; and

(b) maintaining said immunized mammal for
a time period sufficient for the production of
antibodies that bind to CETP.

20

2. The process of claim 1 wherein the blood
of said mammal contains CETP.

25

3. A process for increasing the
concentration of HDL cholesterol in the blood of a
mammal whose blood contains cholesteryl ester transfer
protein (CETP) that comprises the steps of:

(a) immunizing said mammal with an
inoculum containing a vehicle in which is dissolved or
dispersed a recombinant DNA molecule comprising a DNA
sequence that contains (i) a sequence encoding a CETP
immunogen linked to (ii) a promoter sequence that
controls the expression of said CETP immunogen DNA
sequence in said mammal, said CETP immunogen being an
immunogenic polypeptide having a CETP amino acid residue
35

sub
A1 C1

10

Sub C2

sub
A2 C3

30

009436 001997

sequence, said immunization providing an amount of said recombinant DNA molecule sufficient to induce antibodies to CETP; and

(b) maintaining said immunized mammal for a time period sufficient for said CETP immunogen to be expressed and for the production of antibodies that bind to CETP and lessen the transfer of cholesteryl esters from HDL.

4. The process according to claim 3 wherein said immunizing step is repeated.

5. The process according to claim 3 wherein said immunizing step is repeated at intervals of about 3 to about 6 months until the HDL cholesterol value in the blood of said mammal is increased by about 10 percent or more relative to the HDL cholesterol value prior to said first immunization step.

6. The process according to claim 3 wherein said recombinant DNA molecule encodes human CETP as said immunogenic polypeptide

7. The process according to claim 3 wherein said recombinant DNA molecule encodes rabbit CETP as said immunogenic polypeptide.

8. The process according to claim 3 wherein said encoded CETP immunogen comprises an immunogenic polypeptide fused to an exogenous antigenic carrier polypeptide.

9. The process according to claim 8 wherein said exogenous antigenic carrier polypeptide is selected

5

10

15

20

25

30

08934367 091897

Sub
A2
A2
A2

Sub C4

Sub
A3

from the group consisting of hepatitis B core protein, tetanus toxoid, and diphtheria toxoid.

5 10. The process according to claim 9 wherein said recombinant DNA molecule encodes a fusion protein in which said exogenous antigenic carrier is fused to the carboxy-terminus of said immunogenic polypeptide.

10 11. The process according to claim 8 wherein the carboxy-terminus of said encoded exogenous antigenic carrier is fused to the amino-terminus of said encoded immunogenic polypeptide.

15 12. The process according to claim 8 wherein said encoded exogenous antigenic carrier is fused to both the amino-terminus and carboxy-terminus of said encoded immunogenic polypeptide.

20 13. The process according to claim 12 wherein said encoded fusion protein is comprised of an immunogenic polypeptide having a length of about 10 to about 30 amino acid residues that are fused to an amino-terminal flanking sequence and a carboxy-terminal flanking sequence, wherein

25 (a) said amino-terminal flanking sequence consists essentially of about 10 to about 20 amino acid residues having an amino acid residue sequence of the hepatitis B core protein (HBcAg) from about position 1 to about position 35, and said carboxy-
30 terminal sequence consists essentially of about 120 to about 160 amino acid residues having an amino acid residue sequence of HBcAg from about position 10 about position 183, or

35 (b) said amino-terminal flanking sequence consists essentially of about 70 to about 90 residues

20250313 091997

sub
a3
concluded

sub C5

5

10

15

20

25

30

Sub Q4

19. The inoculum of claim 17 wherein said vehicle is phosphate-buffered saline.

5 20. The inoculum of claim 17 wherein said vehicle is isotonic sucrose.

21. The inoculum of claim 17 wherein said DNA is complexed with liposomes.

10

add
05 7

20250709 14:00:00